Ratings for Lineage Cell Therapeutics (AMEX:LCTX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of ...
7 analysts have shared their evaluations of Lineage (NASDAQ:LINE) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of ...
Lineage is reiterated as a buy, trading at a significant discount to NAV and intrinsic value estimates, with strong recovery potential. LINE offers a ~6.1% dividend yield at a sustainable ~64% payout ...
Lineage, Inc. (NASDAQ: LINE), announced that it will report its financial results for the fourth quarter and full year of 2025 on Wednesday, February 25, 2026, before market open. A conference call to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results